Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Invion ( (AU:IVX) ).
Invion Limited announced the issuance of 230,093 fully paid ordinary shares following the exercise of unlisted options. The company is actively engaging with potential contract research organizations and capital providers to expand its clinical trial and research program. Additionally, Invion is in preliminary discussions with RMW Cho Group Ltd to extend its rights to the Photosoft™ technology to new territories or indications, although no binding agreements have been finalized. These developments could potentially enhance Invion’s operational capabilities and market positioning in the life-science industry.
More about Invion
Invion is a life-science company specializing in the global research and development of Photosoft™ technology, which is used for treating various cancers. The company holds the license rights to this technology in Australia and New Zealand, with research and clinical trials funded by RMW Cho Group Limited. Invion is listed on the Australian Securities Exchange (ASX: IVX).
Average Trading Volume: 116,783
Technical Sentiment Signal: Sell
Current Market Cap: A$7.52M
See more insights into IVX stock on TipRanks’ Stock Analysis page.